Mogamulizumab, also known as KW-0761 and bearing the chemical identifier 1159266-37-1, represents a unique approach to treating cutaneous T-cell lymphoma (CTCL). This humanized monoclonal immunoglobulin selectively https://www.targetmol.com/compound/mogamulizumab